rs352140 — TLR9

TLR9 and the CpG Sensor — When Immune Vigilance Comes at a Cost

Toll-like receptor 9 (TLR9)¹¹ Toll-like receptor 9 (TLR9)
TLR9 is an endosomal pattern recognition receptor that detects unmethylated CpG dinucleotide motifs — a molecular signature abundant in bacterial and viral DNA but rare in methylated mammalian genomic DNA is one of the body's most important early-warning sensors for microbial invasion. The rs352140 variant, located in exon 2 of the TLR9 gene at position 2848 of the coding sequence, is synonymous at the protein level — the amino acid sequence of TLR9 is unchanged. Yet despite producing an identical protein, this variant measurably alters TLR9 mRNA expression levels²² this variant measurably alters TLR9 mRNA expression levels
Multiple independent studies have shown that T allele carriers have higher TLR9 transcript levels in immune cells and placental tissue, making it a regulatory variant disguised as a silent mutation.

The T allele (described as the A allele in some older literature using gene-strand notation) is strikingly common — carried by roughly half of Europeans and about a third of East Asians and Africans. This high frequency makes rs352140 one of the most studied TLR9 polymorphisms, with over 129 publications examining its role across infections, autoimmune diseases, and cancer susceptibility.

The Mechanism

TLR9 resides inside endosomes — membrane-bound compartments where degraded microbial material is processed after phagocytosis. When bacterial or viral DNA containing unmethylated CpG sequences arrives in the endosome, TLR9 binds these motifs and triggers a signaling cascade through MyD88 and TRAF6³³ MyD88 and TRAF6
Key adaptor proteins in innate immune signaling that activates NF-κB and interferon regulatory factors (IRFs). The result is rapid production of pro-inflammatory cytokines (IL-6, TNF-α, IL-12) and type I interferons (IFN-α, IFN-β) — the first-line molecular alarm system for infections.

Although rs352140 does not change the TLR9 protein sequence, it appears to affect mRNA stability or splicing efficiency⁴⁴ it appears to affect mRNA stability or splicing efficiency
Synonymous variants can alter codon usage, mRNA secondary structure, and ribosome elongation speed, all of which affect protein output. T allele carriers show higher TLR9 expression, meaning their innate immune cells produce more TLR9 receptors and therefore mount amplified responses when CpG DNA is detected. This heightened sensitivity is a double-edged sword: more responsive to genuine pathogens, but also more prone to over-activation by self-DNA released during cell death — the proposed mechanism linking TLR9 to autoimmunity.

The Evidence

The clinical literature on rs352140 is extensive but heterogeneous, reflecting the variant's involvement in multiple biological contexts.

Placental inflammation and preterm birth: A study of 159 infants found that CT/TT genotype carriers had 3.8–4.2-fold higher odds of placental inflammation compared to CC homozygotes (OR 4.2, 95% CI 1.5–11.4, p=0.005)⁵⁵ A study of 159 infants found that CT/TT genotype carriers had 3.8–4.2-fold higher odds of placental inflammation compared to CC homozygotes (OR 4.2, 95% CI 1.5–11.4, p=0.005)
Association held after adjusting for confounders including gestational age and rupture of membranes. The maternal pattern of inflammation — suggesting maternal immune activation at the placenta — was 100% penetrant in preterm infants with CT/TT genotype. The proposed mechanism is enhanced TLR9 recognition of bacterial CpG motifs at the maternal-fetal interface, triggering excessive inflammatory responses.

Type 1 diabetes: In 1,513 Han Chinese participants, the T allele conferred significantly elevated T1D risk (OR=1.19, 95% CI 1.03–1.39, p=0.019), with the TT genotype showing stronger effect (OR=1.54, 95% CI 1.11–2.13, p=0.010)⁶⁶ In 1,513 Han Chinese participants, the T allele conferred significantly elevated T1D risk (OR=1.19, 95% CI 1.03–1.39, p=0.019), with the TT genotype showing stronger effect (OR=1.54, 95% CI 1.11–2.13, p=0.010)
Study from Central South University, published 2023. The proposed mechanism involves enhanced TLR9-mediated type I interferon production activating autoreactive T cells targeting pancreatic beta cells.

Cancer: A meta-analysis of 14,091 subjects found that TT genotype carriers had increased cancer risk in Caucasians (OR=1.40 in recessive model, 95% CI 1.02–1.92, p=0.039)⁷⁷ A meta-analysis of 14,091 subjects found that TT genotype carriers had increased cancer risk in Caucasians (OR=1.40 in recessive model, 95% CI 1.02–1.92, p=0.039)
Analysis covered bladder cancer, ALL, hepatocellular carcinoma, Hodgkin lymphoma, and breast cancer. A separate meta-analysis found a protective effect against breast cancer specifically in African Americans (GA vs GG: OR=0.77). These divergent findings across cancer types suggest the direction of risk depends on the specific tissue, immune microenvironment, and pathogen exposure history.

Behçet's disease: In 205 Iranian BD patients and 207 controls, CT and combined TT+CT genotypes were more frequent in healthy controls than patients (p=0.01), suggesting these genotypes protect against BD⁸⁸ In 205 Iranian BD patients and 207 controls, CT and combined TT+CT genotypes were more frequent in healthy controls than patients (p=0.01), suggesting these genotypes protect against BD
Effect strongest in females. This paradox — the same T allele that increases cancer and T1D risk appears protective against BD — illustrates how TLR9 variants have context-dependent effects depending on which immune pathways dominate in each disease.

Systemic lupus erythematosus: Individual studies have linked rs352140 to SLE susceptibility, lupus nephritis, and elevated anti-dsDNA antibodies (OR ~3.7 for TT/CT genotypes for immunologic disorders). However, a 2023 meta-analysis pooling genetic association studies found no statistically significant overall SLE association in any genetic model across Asian, European, or Latin American ancestry groups⁹⁹ a 2023 meta-analysis pooling genetic association studies found no statistically significant overall SLE association in any genetic model across Asian, European, or Latin American ancestry groups
PMID 37265090, suggesting the association may be population-specific or confounded by linkage disequilibrium with nearby causal variants.

Practical Implications

The T allele's signature is increased TLR9-mediated immune vigilance. For most people, this translates to a somewhat heightened innate immune tone — potentially beneficial for clearing infections but carrying modestly elevated risk for immune-mediated conditions. The evidence is clearest for placental inflammation and type 1 diabetes risk; the cancer associations require confirmation across additional populations and cancer types.

For individuals with CT or TT genotypes, the practical implications center on monitoring immune-mediated conditions (particularly autoimmune disorders, inflammatory states during pregnancy, and cancer screening), rather than lifestyle modifications that would alter the genetic effect. There are no known dietary or supplement interventions that specifically modulate TLR9 expression in clinically meaningful ways.

Interactions

The rs352140 variant is often studied alongside the TLR9 promoter variant [rs187084 (-1486T/C) | Located in the TLR9 gene promoter region, this variant also affects transcription factor binding and TLR9 expression], and these two SNPs are frequently inherited together as a haplotype. Combined haplotype analyses generally show stronger associations than either SNP alone, particularly for SLE and hepatitis susceptibility. The TLR9 pathway also intersects with [TLR2 (rs5743708) | TLR2 recognizes bacterial lipoproteins and peptidoglycan, a complementary pathway to TLR9's DNA sensing] and [TLR4 (rs4986790) | TLR4 detects bacterial LPS], such that individuals carrying risk variants in multiple toll-like receptors have altered innate immune profiles affecting susceptibility to diverse pathogens and inflammatory conditions.